FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104116564> ?p ?o ?g. }

• W2104116564 endingPage "744" @default.
• W2104116564 startingPage "736" @default.
• W2104116564 abstract "Purpose: We investigated the role of intraoperative iodine-125 (125I) brachytherapy as a treatment option for unresectable primary and metastatic liver tumors. Methods and Materials: Between 1989 and 2002, 64 patients with unresectable or residual disease after surgical resection for intrahepatic malignancies underwent 160-Gy permanent 125I brachytherapy. Results: The median length of follow-up was 13.2 years. The overall 1-year, 3-year, and 5-year actuarial intrahepatic local control rates were 44%, 22%, and 22%, respectively, with a median time to liver recurrence of 9 months (95% CI, 6–12 months). The 5-year actuarial intrahepatic control was higher for patients with solitary metastasis (38%) than for those with multiple metastases (6%, p = 0.04). The 1-year, 3-year, and 5-year actuarial overall survival rates were 73%, 23%, and 5%, respectively (median, 20 months; 95% CI, 16–24; longest survival, 7.5 years). Overall survival was higher for patients with smaller-volume implants (p = 0.003) and for patients without prior liver resection (p = 0.002). No mortality occurred. Radiation-related complications were minimal. Conclusions: For select patients with unresectable primary and metastatic liver tumors for whom curative surgical resection is not an option, 125I brachytherapy is a safe and effective alternative to other locally ablative techniques and can provide long-term local control and increased survival. Purpose: We investigated the role of intraoperative iodine-125 (125I) brachytherapy as a treatment option for unresectable primary and metastatic liver tumors. Methods and Materials: Between 1989 and 2002, 64 patients with unresectable or residual disease after surgical resection for intrahepatic malignancies underwent 160-Gy permanent 125I brachytherapy. Results: The median length of follow-up was 13.2 years. The overall 1-year, 3-year, and 5-year actuarial intrahepatic local control rates were 44%, 22%, and 22%, respectively, with a median time to liver recurrence of 9 months (95% CI, 6–12 months). The 5-year actuarial intrahepatic control was higher for patients with solitary metastasis (38%) than for those with multiple metastases (6%, p = 0.04). The 1-year, 3-year, and 5-year actuarial overall survival rates were 73%, 23%, and 5%, respectively (median, 20 months; 95% CI, 16–24; longest survival, 7.5 years). Overall survival was higher for patients with smaller-volume implants (p = 0.003) and for patients without prior liver resection (p = 0.002). No mortality occurred. Radiation-related complications were minimal. Conclusions: For select patients with unresectable primary and metastatic liver tumors for whom curative surgical resection is not an option, 125I brachytherapy is a safe and effective alternative to other locally ablative techniques and can provide long-term local control and increased survival." @default.
• W2104116564 created "2016-06-24" @default.
• W2104116564 creator A5005037839 @default.
• W2104116564 creator A5026579804 @default.
• W2104116564 creator A5043982157 @default.
• W2104116564 creator A5083008292 @default.
• W2104116564 creator A5085287368 @default.
• W2104116564 date "2006-03-01" @default.
• W2104116564 modified "2023-09-25" @default.
• W2104116564 title "Long-term follow-up of patients of intrahepatic malignancies treated with Iodine-125 brachytherapy" @default.
• W2104116564 cites W1029869927 @default.
• W2104116564 cites W1491010061 @default.
• W2104116564 cites W1696496287 @default.
• W2104116564 cites W1778822017 @default.
• W2104116564 cites W1964915929 @default.
• W2104116564 cites W1965373246 @default.
• W2104116564 cites W1969108629 @default.
• W2104116564 cites W1972358289 @default.
• W2104116564 cites W1975503701 @default.
• W2104116564 cites W1976158860 @default.
• W2104116564 cites W1976966111 @default.
• W2104116564 cites W1979566969 @default.
• W2104116564 cites W1985334064 @default.
• W2104116564 cites W1985981281 @default.
• W2104116564 cites W1986226397 @default.
• W2104116564 cites W1989175303 @default.
• W2104116564 cites W1992421431 @default.
• W2104116564 cites W1994752553 @default.
• W2104116564 cites W1999805343 @default.
• W2104116564 cites W2000162663 @default.
• W2104116564 cites W2002440649 @default.
• W2104116564 cites W2002978889 @default.
• W2104116564 cites W2003170690 @default.
• W2104116564 cites W2005292676 @default.
• W2104116564 cites W2007216505 @default.
• W2104116564 cites W2011357655 @default.
• W2104116564 cites W2016436045 @default.
• W2104116564 cites W201834716 @default.
• W2104116564 cites W2024184487 @default.
• W2104116564 cites W2031811526 @default.
• W2104116564 cites W2035779983 @default.
• W2104116564 cites W2037984373 @default.
• W2104116564 cites W2041027930 @default.
• W2104116564 cites W2041212391 @default.
• W2104116564 cites W2046824607 @default.
• W2104116564 cites W2048993581 @default.
• W2104116564 cites W2057418229 @default.
• W2104116564 cites W2060163561 @default.
• W2104116564 cites W2063619032 @default.
• W2104116564 cites W2068298237 @default.
• W2104116564 cites W2069178799 @default.
• W2104116564 cites W2069853951 @default.
• W2104116564 cites W2071264740 @default.
• W2104116564 cites W2072788416 @default.
• W2104116564 cites W2074073423 @default.
• W2104116564 cites W2077645480 @default.
• W2104116564 cites W2079190855 @default.
• W2104116564 cites W2081354741 @default.
• W2104116564 cites W2084440537 @default.
• W2104116564 cites W2084470612 @default.
• W2104116564 cites W2086649575 @default.
• W2104116564 cites W2087435831 @default.
• W2104116564 cites W2098350825 @default.
• W2104116564 cites W2107840136 @default.
• W2104116564 cites W2111910408 @default.
• W2104116564 cites W2125551462 @default.
• W2104116564 cites W2128726365 @default.
• W2104116564 cites W2138826896 @default.
• W2104116564 cites W2160535919 @default.
• W2104116564 cites W2170723766 @default.
• W2104116564 cites W283717366 @default.
• W2104116564 cites W4246295292 @default.
• W2104116564 doi "https://doi.org/10.1016/j.ijrobp.2005.08.029" @default.
• W2104116564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16274935" @default.
• W2104116564 hasPublicationYear "2006" @default.
• W2104116564 type Work @default.
• W2104116564 sameAs 2104116564 @default.
• W2104116564 citedByCount "54" @default.
• W2104116564 countsByYear W21041165642012 @default.
• W2104116564 countsByYear W21041165642013 @default.
• W2104116564 countsByYear W21041165642014 @default.
• W2104116564 countsByYear W21041165642015 @default.
• W2104116564 countsByYear W21041165642016 @default.
• W2104116564 countsByYear W21041165642017 @default.
• W2104116564 countsByYear W21041165642018 @default.
• W2104116564 countsByYear W21041165642019 @default.
• W2104116564 countsByYear W21041165642020 @default.
• W2104116564 countsByYear W21041165642021 @default.
• W2104116564 countsByYear W21041165642022 @default.
• W2104116564 countsByYear W21041165642023 @default.
• W2104116564 crossrefType "journal-article" @default.
• W2104116564 hasAuthorship W2104116564A5005037839 @default.
• W2104116564 hasAuthorship W2104116564A5026579804 @default.
• W2104116564 hasAuthorship W2104116564A5043982157 @default.
• W2104116564 hasAuthorship W2104116564A5083008292 @default.
• W2104116564 hasAuthorship W2104116564A5085287368 @default.
• W2104116564 hasConcept C121608353 @default.
• W2104116564 hasConcept C126322002 @default.

• next